Details of the Drug
General Information of Drug (ID: DMG49N2)
Drug Name |
2-(2,4-diphenylthiazol-5-yl)acetic acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-(2,4-diphenyl-1,3-thiazol-5-yl)acetic acid; 21256-15-5; 2-(2,4-diphenylthiazol-5-yl)acetic acid; CHEMBL592001; SMR000168586; diphenylthiazolylaceticacid; Bionet2_000936; AC1MC90U; Oprea1_148343; MLS000327963; SCHEMBL4497493; CTK4E6215; DTXSID40377203; MolPort-002-345-061; ZINC169124; HMS2377A22; HMS1366K12; KS-00001A6R; 7213AD; SBB077302; BDBM50309445; AKOS005070458; RP15938; MCULE-6578968783; 4K-539S; (diphenyl-1,3-thiazol-5-yl)acetic acid; AM803507; AJ-17064; KB-220568; TR-009976; CS-0039039; FT-0680367; I04-4316; J-505484
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 295.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||